Gilead reports $5.8 billion in sales of hepatitis C drug
- Written by Editor
- Published in News Feeds
Amid concerns over the high cost of its new treatment for hepatitis C, drugmaker Gilead Sciences Inc. reported $5.8 billion in sales for its blockbuster Sovaldi drug in the first half of 2014....
Read more http://www.latimes.com/la-fi-hep-c-prices-20140724-story.html?track=rss